Featured Publications
Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States
Patell R, Midha S, Kimani S, Martin R, Neparidze N, Jaglal M, Freed J, Key NS. Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States. Thrombosis And Haemostasis 2020, 120: 1725-1732. PMID: 32828072, PMCID: PMC7869034, DOI: 10.1055/s-0040-1715837.Peer-Reviewed Original ResearchAssociation of iron infusion reactions with ABO blood type
Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.Peer-Reviewed Original ResearchConceptsGreater oddsBlood typeYale Cancer CenterInfusion-related reactionsRetrospective chart reviewLarger patient numbersABO blood typeType AB bloodChart reviewInfusion reactionsMost patientsHematology clinicIron sucroseMultivariable analysisProspective studyCancer CenterPatient numbersIron dextranRisk factorsIron infusionIron repletionPatientsPossible associationAB bloodBloodChanges in multiple myeloma treatment patterns during the early COVID-19 pandemic period
Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia 2022, 36: 2136-2139. PMID: 35761025, PMCID: PMC9243711, DOI: 10.1038/s41375-022-01633-x.Peer-Reviewed Original ResearchRefractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report
Crawford LR, Neparidze N. Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report. Clinical Case Reports 2022, 10: e05583. PMID: 35340637, PMCID: PMC8933632, DOI: 10.1002/ccr3.5583.Peer-Reviewed Original ResearchAutoimmune hemolytic anemiaSystemic lupus erythematosusRefractory autoimmune hemolytic anemiaHemolytic anemiaMycophenolate mofetilWarm autoimmune hemolytic anemiaSystemic lupus erythematosus patientsIntravenous immune globulinLupus erythematosus patientsClinical case reportNovel therapeutic modalitiesB cell proliferationImmune globulinSystemic lupusLupus erythematosusPediatric casesAdult casesCase reportHematologic disordersPlasma cellsTherapeutic modalitiesPatientsBeneficial responseAnemiaIndividuals/year
2024
Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights
Muradashvili T, Liu Y, VanOudenhove J, Gu S, Krause D, Montanari F, Carlino M, Mancuso R, Stempel J, Halene S, Zeidan A, Podoltsev N, Neparidze N. Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights. Leukemia & Lymphoma 2024, ahead-of-print: 1-8. PMID: 39225418, DOI: 10.1080/10428194.2024.2393260.Peer-Reviewed Original ResearchAplastic anemiaMultiple myelomaImmunosuppressive therapyTransfusion requirementsProgenitor cellsPlasma cell-directed therapyT-cell destructionCell-directed therapiesInhibition of erythroid colony formationErythroid colony formationLevels of IL8Severe AAImmune cytopeniasPartial responseMM patientsHematopoietic stemSerum testsPartial improvementPathophysiological insightsPatientsImmune systemPlatelet apoptosisCytopeniasColony formationMyelomaP-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchMM-416 Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study
Neparidze N, Godara A, Godara D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. MM-416 Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s555-s556. DOI: 10.1016/s2152-2650(24)01678-1.Peer-Reviewed Original ResearchImpact of social needsMixed-methods studyPatient experienceSocial needsImprove patient experienceChronic health conditionsMental health burdenAssess sociodemographic characteristicsSemi-structured group discussionsFocus group participantsMental health concernsLack of insuranceBurden of illnessFear of relapseGroup of US patientsCare journeyMultiple myelomaHealth outcomesMental healthSocial supportSociodemographic characteristicsFocus groupsHealth conditionsGroup participantsMixed-methodsImpact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study
Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s238. DOI: 10.1016/s2152-2650(24)00965-0.Peer-Reviewed Original ResearchPrevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Peer-Reviewed Original ResearchImpact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study
Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study. Healthcare 2024, 12: 1660. PMID: 39201218, PMCID: PMC11353550, DOI: 10.3390/healthcare12161660.Peer-Reviewed Original ResearchMixed-methods studyImpact of social needsHealth burdenChronic health conditionsMental health burdenPhysical health burdenFocus group participantsMental health concernsLack of insuranceBurden of illnessSocial needsCare journeyHealth outcomesDisease journeySocial supportFocus groupsHealth conditionsGroup participantsLack of knowledgeMultiple myelomaUnmet needsMixed-methodsFinancial concernsHigher anxietyHealth concernPatient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities
Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities. Healthcare 2024, 12: 1587. PMID: 39201146, PMCID: PMC11354118, DOI: 10.3390/healthcare12161587.Peer-Reviewed Original ResearchDisease journeyHealth care providersImprove patient supportCare providersPatient prioritiesPatient advocatesPatient perspectiveMedical appointmentsMultiple myelomaPatient supportMultiple barriersInformed treatment decisionsPrioritized needsMultidisciplinary teamTreatment adherenceDisease burdenFocus group researchComprehensive supportImprove outcomesSocial workersTreatment decisionsInsurance optionsMixing methodBurdenSupportAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucelRacial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatmentRacial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States
Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.Peer-Reviewed Original ResearchAcute myelogenous leukemiaMantle cell lymphomaChronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMultiple myelomaWhite patientsBlack patientsCell lymphomaHematologic malignanciesLymphocytic leukemiaTreatment categoriesElectronic health record (EHR)-derived de-identified databaseDiagnosis of acute myelogenous leukemiaLarge B-cell lymphomaTelemedicine uptakeActive patientsLines of therapyB-cell lymphomaMonthly visit ratesMyeloma patientsVisit ratesAnalyzed patientsMyelogenous leukemiaLymphoma
2023
CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediatorsMultimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders
Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.Peer-Reviewed Original ResearchBleeding tendencyBleeding disorderPlatelet markersPlatelet aggregometryMass cytometryPlatelet functionPlatelet disordersSingle-center prospective studyLow-risk groupAbnormal bleeding tendencyQualitative platelet disordersLarge patient cohortQuantitative platelet disordersCommon underlying causeGenetic variantsMultimodality evaluationTotal patientsRisk stratificationLaboratory suspicionPlatelet dysfunctionProspective studyPatient cohortUnivariate analysisPlatelet volumeRisk groupsA Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma
Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma. Blood 2023, 142: 7353. DOI: 10.1182/blood-2023-178893.Peer-Reviewed Original ResearchBurden of illnessMental health burdenMultiple myelomaPhysical health burdenHealth burdenDisease burdenSide effectsBACKGROUND Multiple myelomaMM patient populationsRelated care processesFive-year survivalRisk of progressionTreatment side effectsRecent treatment advancesChronic health conditionsLack of cureGroup sessionsSemi-structured focus group sessionsHalf of participantsFocus group sessionsRace/ethnicityMost patientsMedical oncologistsMM patientsDisease journeyReal-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study
Theprungsirikul P, Liu Y, Neparidze N. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study. Blood 2023, 142: 7364. DOI: 10.1182/blood-2023-186985.Peer-Reviewed Original ResearchFront-line treatmentBone marrow plasma cellsCommunity practice settingsR-ISS stageECOG performance statusRetrospective observational studyPerformance statusTransplant eligibilityPractice settingsCytogenetic abnormalitiesBone lesionsInsurance typeObservational studyTreatment responseEastern Cooperative Oncology Group performance statusInternational Myeloma Working Group criteriaYale New Haven Health SystemInternational Staging System stageRefractory multiple myeloma patientsUnfavorable-risk cytogeneticsGood partial responseFront-line therapyCD38 monoclonal antibodyMultiple myeloma patientsBetter treatment responseP-098 Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Neparidze N. P-098 Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s88-s89. DOI: 10.1016/s2152-2650(23)01716-0.Peer-Reviewed Original ResearchOlder patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare access